OTLK Outlook Therapeutics Inc

$OTLK — payer coverage rollout has officially started. 👀 Superior HealthPlan is updating its bevacizumab policy effective Dec. 1, 2026, explicitly adding LYTENAVA for nAMD across several of its health plans. This is exactly what we wanted to see ahead of launch: FDA approval → pricing → J-code/HCPCS → payer policies → patient access → prescriptions. One payer alone won’t move the needle, but if more insurers start publishing similar coverage updates over the coming weeks, the commercial setup for LYTENAVA could be much stronger than the market currently expects. The reimbursement story is starting to become real. 🔥

$OTLK just watched the interview of the new CFO. Sounds indeed promising. If I compare him with the former CFO, I really wonder how this company survived at all. Unfortunately the old management has destroyed so much of shareholder trust, that the market no longer rewards nice words. They need to deliver. But I feel certainly better with him overtaking.

$OTLK “We remain focused on executing across market access, reimbursement, commercial readiness and supply ahead of our planned U.S. launch before the end of 2026.”

$OTLK If the company is clearly on track toward the $500M peak and has the J-code, growing sequential sales, and limited further dilution, a 4–6× salesmultiple is a reasonable expectation. So hitting ~$250M in the next 18–20 months would put the stock in the mid-single digits on today’s outstanding shares, with $4–$6 being the most probable band if execution stays on track. I’ll keep loading and wait for **Summer 2028 $5**

$OTLK here’s the PR I want to see… Outlook Therapeutics Enters into Definitive Agreement to Be Acquired by [Buyer] at $ 7 Per Share

$OTLK 🆕 UnitedHealthcare adds LYTENAVA to its October 2026 Medical Benefit drug review process. As of October 1, 2026, UHC explicitly lists LYTENAVA™ (bevacizumab-vikg) in its new-to-market “Review at Launch” process for provider-administered medical-benefit drugs. This applies to UnitedHealthcare Commercial and Community Plan. With more than 30 million people served through its Commercial business, UHC is a major U.S. payer. Another important step in the U.S. commercialization and reimbursement infrastructure for LYTENAVA. Source: UnitedHealthcare Provider, October 2026 Medical Benefit Drug / Specialty Medical Injectable updates.

$OTLK With an FDA-approved product targeting an $8.5B U.S. anti-VEGF retina market within a global market of more than $15.9B, and OTLK essentially ready for a U.S. launch before the end of 2026, a share price below $0.60 seems difficult to justify in my personal view. The commercial execution now has to prove the market wrong. DO IT

$OTLK This is where the market gets really interesting. KOD is now valued at roughly $5–6 billion after today’s positive Phase 3 data. Yet Kodiak is still pre-commercial, has no product revenue, and reported a $65.6M net loss in Q2 2026. $OTLK, meanwhile, is already FDA-approved, has a $485 WAC, and is approaching US commercialization — yet is valued at roughly $150 million around $0.61. $5–6B vs. ~$150M. One is being valued on future potential. The other is approaching actual commercialization and revenue. That valuation gap is hard to ignore

$OTLK suggest everybody watched the CFO interview. That’s been posted. Pretty impressive career. High hopes.

$OTLK why does this have nearly 1 million shares traded premarket ? .... volume .... does someone know something and front running ?

$OTLK If I was OTLK this is what my plan would be. I would have a limited-time introductory price or a bridge/co-pay assistance program. I would set the expiration date to be the very date the permanent J code is assigned. If doctors can get it for the same price as Avastin, why not give it a try? When the permanent code comes, they just keep using it at the regular price. That would make the income ramp dramatic at J code time.

$OTLK The base case numbers are not calculated using possible conversion from off label as the only driver of sales. They are calculated using conversion from off label plus picking up a reasonably expected amount of the massive increase in cases per year. Compounding pharmacies do not have the capacity to meet the increase in demand. They have no intention of increasing capacity. This is evidenced by Pine's decision to stop compounding Avastin. To make the numbers work you need to see the whole picture. Should the FDA step in and enforce the rules this could turn massive. That is why they said base case. (They do not need to stop Avastin to achieve those numbers)

$OTLK LYTENAVA could justify a valuation above $1B if Outlook demonstrates sufficient commercial penetration; today, the market still isn’t willing to assign that valuation before seeing execution.

$OTLK The economic moat surrounding OTLK is most insurers require "step therapy", using cheaper drugs first to assess a patients healing response. Zenkuda application for FDA approval possible in 2026 with another 9 month evaluation, will not be commercial till mid 2028. OTLK at 4.00++

$OTLK — I have a strong feeling an upfront/advance payment tied to a licensing or commercialization deal for Asia or Europe could be very close. With LYTENAVA approaching launch in the U.S., securing a non-dilutive upfront payment from an ex-U.S. partner would be exactly the kind of catalyst the market is not pricing in right now. Asia or Europe. Something may be close to closing. 👀

$OTLK I’m just DCAing into this for the rest of the year and maybe next. If you can stomach the BS until 2030 and treat this as a longer term investment you will probably 10x easily from here. I’m not sure where else you could find gains like that in 3-4 years.

$OTLK added More today, also noticed on Robert Hood. The cost to borrow for shorts is gone up to 6%.

$OTLK Added more. Its Honestly kind of Insane to see it at these Prices - the second there is Positive news we will soar to 1$. The Market is there, they have cash on hand, even the Warrants are a decent thing - as once we hit 1,10 they are ITM and can bring in more cash. Do your own research, but i am quite positive, even with the downtrend we have head since approval. Let them do the proper rollout, they have hired good People with all the Knowledge they need.

$OTLK With the updates over the weekend like with United Health already, that low target should bump up soon from $1.60. Plenty of room to run. The current price has got to be artificial BS.

$OTLK All those new investors who will buy shares in next couple of months will be making 5x-10x within a year. But this might not be true for old holders 🙄